Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) for allegedly making false statements regarding the FDA's feedback on their drug relacorilant, which may have misled investors [2][4]. Group 1: Allegations and Legal Context - The class period for the lawsuit is defined as October 31, 2024, to December 30, 2025 [2]. - The complaint alleges that Corcept concealed concerns from the FDA regarding the adequacy of the relacorilant program for treating hypertension in patients with hypercortisolism, including issues with the GRACE study design [2]. - Defendants reportedly made materially false or misleading statements about their interactions with the FDA and the likelihood of NDA approval for relacorilant [2]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased CORT shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for April 21, 2026 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Mission and Commitment - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock price [4].

Core Viewpoint - The Gross Law Firm is investigating potential securities fraud claims on behalf of investors who incurred losses in Agios Pharmaceuticals, Inc. (AGIO) [1] Group 1 - The investigation is prompted by concerns over possible deceitful practices that may have led to artificial inflation of AGIO's stock [2] - Investors who suffered losses are encouraged to contact the law firm to discuss their rights [1][2] - The Gross Law Firm emphasizes its commitment to protecting investor rights and ensuring companies adhere to responsible business practices [2]

Group 1 - The U.S. Food and Drug Administration (FDA) has declined to approve Aldeyra Therapeutics' drug for a specific type of eye disease [1] - This decision represents a setback for Aldeyra Therapeutics, which was seeking approval for its treatment [1] Group 2 - The FDA's rejection may impact Aldeyra's stock performance and investor sentiment [1]

Core Viewpoint - Cencora, Inc. announces the retirement of James F. Cleary as Executive Vice President and Chief Financial Officer effective June 30, 2026, while reaffirming its fiscal 2026 financial guidance for adjusted diluted EPS in the range of $17.45 to $17.75 [1][3]. Leadership Transition - James F. Cleary has served as CFO since November 2018 and joined Cencora in February 2015 after the acquisition of MWI Veterinary Supply, where he was CEO for over a decade [2]. - The company has engaged an executive search firm to identify potential successors, and Cleary will assist in the transition process until the end of 2026 [1][3]. Financial Guidance - Cencora reaffirms its adjusted diluted EPS guidance for fiscal year 2026, maintaining a range of $17.45 to $17.75 [3]. Company Overview - Cencora is a leading global pharmaceutical solutions organization with over 51,000 employees and annual revenue exceeding $300 billion, ranked 10 on the Fortune 500 and 18 on the Global Fortune 500 [4].

Core Viewpoint - Achieve Life Sciences, Inc. is set to report its fourth quarter and full year 2025 financial results on March 24, 2026, alongside updates on the cytisinicline development program [1] Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline for nicotine dependence treatment [3] - The company submitted a New Drug Application (NDA) to the FDA in June 2025, which has been accepted for review, with a PDUFA date set for June 20, 2026 [3] - Cytisinicline is intended for smoking cessation in adults, supported by two completed Phase 3 studies and an open-label safety study [3] Industry Context - Approximately 25 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death, resulting in over 8 million deaths globally and nearly 500,000 in the U.S. annually [4] - There are nearly 18 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for e-cigarette cessation [5] - The FDA has recognized the need for e-cigarette cessation treatments by awarding a National Priority Voucher and granting Breakthrough Therapy designation [5] Product Information - Cytisinicline is a plant-based alkaloid that binds to nicotinic acetylcholine receptors, potentially aiding in nicotine addiction treatment by reducing cravings and satisfaction associated with nicotine [6] - The product is still investigational and has not yet received FDA approval for any indication in the U.S. [6]

Core Viewpoint - A securities class action lawsuit has been filed against Aquestive Therapeutics, Inc. on behalf of investors who purchased or acquired its securities between June 16, 2025, and January 8, 2026, alleging violations of the Securities Exchange Act of 1934 [1][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey, claiming that the company and certain senior officers made misrepresentations regarding the New Drug Application for Anaphylm (Dibutepinephrine) sublingual film [5][6]. - Investors are encouraged to join the class action and can contact the Investor Relations Manager for more information [3][9]. Group 2: Participation Information - Individuals wishing to serve as lead plaintiff must file papers by May 4, 2026, and participation does not require serving as lead plaintiff to share in any recovery [4]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 and has a strong track record in class action litigation [7].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Corcept Therapeutics Incorporated on behalf of investors who purchased or acquired the company's common stock between October 31, 2024, and December 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that the defendants made misrepresentations regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, which is Corcept's lead product candidate for multiple indications, including treatment for hypercortisolism [5] Group 2: Legal Actions and Options - Investors who purchased Corcept common stock are encouraged to discuss their legal rights and options, with contact information provided for the Investor Relations Manager [3] - Individuals wishing to serve as lead plaintiff must file necessary papers by April 21, 2026, and can still share in any recovery without serving as lead plaintiff [4]

Core Insights - Liminatus has announced plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking monoclonal antibody aimed at enhancing immune response against tumors [1][2] Group 1: Clinical Trial Details - The Phase 1 study will begin with monotherapy dose escalation to assess safety, tolerability, and pharmacokinetics, followed by combination cohorts with PD-1/PD-L1 therapies [3] - Lung cancer has been selected as the initial focus of the Phase 1 program, addressing the need for improved patient responses in current treatment paradigms [4] - The trial will be led by Dr. Se-Hoon Lee, an expert in immuno-oncology clinical research, and will include translational analyses to characterize immune activity [5] Group 2: Regulatory and Development Plans - The company plans to engage with regulatory authorities as part of its clinical development strategy and aims to be ready to advance the program after completing necessary manufacturing and regulatory preparations [6]

Core Insights - LENZ Therapeutics, Inc. is focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved eye drop for treating presbyopia in adults [1][3] - The company will host a webcast on March 24, 2026, to report its fourth quarter and full year 2025 financial results and recent corporate highlights [1] Company Overview - LENZ Therapeutics is headquartered in San Diego, California, and is commercializing VIZZ in the United States while establishing international licensing partnerships [3] - Presbyopia affects an estimated 1.8 billion people globally, including 128 million in the United States [3]

Core Viewpoint - Pfizer's experimental drug combination significantly reduces the risk of disease progression or death in breast cancer patients by 40% in a mid-stage trial [1][2]. Group 1: Drug Details - The combination of atirmociclib and fulvestrant was tested in patients with advanced breast cancer who had previously received treatment [2]. - The study compared the experimental drug combination to fulvestrant or everolimus plus exemestane, a common therapy for postmenopausal women with breast cancer [2]. - Over 90% of patients began treatment with atirmociclib within three months of stopping their previous cancer medication [3]. Group 2: Safety and Efficacy - The safety profile of atirmociclib was manageable, with only 6.4% of patients discontinuing treatment due to side effects [3]. - Overall survival data, which is a secondary goal of the study, is still in early stages and not yet conclusive [3]. Group 3: Future Plans - Pfizer plans to test atirmociclib in first-line and early-stage breast cancer to achieve longer-lasting disease control [4]. - A large late-stage study of atirmociclib in newly diagnosed metastatic breast cancer patients is already in progress [4].